News Vertex Pharmaceuticals Incorporated

Stocks

VRTX

US92532F1003

Pharmaceuticals

Market Closed - Nasdaq 16:00:00 2026-09-24 EDT			5-day change	1st Jan Change
522.38 ^USD	+1.17%		+1.17%	+15.22%

09-23	TD Cowen Adjusts PT on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating	MT
09-23	Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $640 From $633, Maintains Buy Rating	MT

All News

Mentions Relevance

09-23	TD Cowen Adjusts PT on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating	MT
09-23	Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $640 From $633, Maintains Buy Rating	MT
09-22	Vertex Pharmaceuticals Incorporated Announces Positive Results From Phase 2b AMPLIFIED Study Of Inaxaplin And Completes Enrollment In The Phase 2/3 AMPLITUDE Trial	CI
09-22	Vertex Pharmaceuticals Reports Positive Results for Inaxaplin Kidney Disease Trial	MT
09-22	Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial	BU
09-15	Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute Pain	BU
09-14	Vertex Pharmaceuticals Incorporated Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-14-2026 07:00 AM
09-10	Vertex Pharmaceuticals Incorporated Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-10-2026 02:10 PM
09-10	Vertex Pharmaceuticals Incorporated Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 04:30 PM
09-02	Evercore ISI Adjusts Vertex Pharmaceuticals Price Target to $600 From $535, Maintains Outperform Rating	MT
09-01	Vertex Pharmaceuticals Incorporated Announces Chief Financial Officer Changes, Effective January 1, 2027	CI
09-01	Vertex Pharmaceuticals Incorporated Appoints Jonathan Poole as Executive Vice President, Effective January 1, 2027	CI
09-01	Vertex Names Jonathan Poole Finance Chief as Crinetics Buy Closes	DJ
09-01	Vertex Pharmaceuticals Closes Crinetics Pharmaceuticals Acquisition	MT
09-01	Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team	BU
08-26	Vertex to Participate in Upcoming September Investor Conferences	BU
08-12	Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says	MT
08-11	Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $633 From $610, Maintains Buy Rating	MT
08-11	Daiwa Securities Adjusts Price Target on Vertex Pharmaceuticals to $556 From $555, Maintains Buy Rating	MT
08-10	Vertex Shares Rise as Rival Sionna's Cystic-Fibrosis Trial Fails to Meet Endpoint	DJ
08-10	Sionna scraps genetic disorder drug program after trial setback; shares tank	RE
08-05	Rothschild & Co Redburn Adjusts Vertex Pharmaceuticals Price Target to $580 From $570	MT
08-04	Vertex Pharmaceuticals Incorporated : Quarterly Report for Quarter Ending JUNE 30, 2026 (Form 10-Q)	PU
08-04	Tranche Update on Vertex Pharmaceuticals Incorporated's Equity Buyback Plan announced on May 19, 2025.	CI
08-04	Vertex Pharmaceuticals Seen Well Positioned Ahead of Pipeline Catalysts, UBS Says	MT